.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Novartis
Covington
Teva
Accenture
Baxter
Daiichi Sankyo
Cantor Fitzgerald
McKesson
Harvard Business School

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022524

« Back to Dashboard
NDA 022524 describes ZUPLENZ, which is a drug marketed by Midatech Pharma Us and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug. Additional details are available on the ZUPLENZ profile page.

The generic ingredient in ZUPLENZ is ondansetron. There are twenty-eight drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the ondansetron profile page.

Summary for NDA: 022524

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:2
Formulation / Manufacturing:see details

Pharmacology for NDA: 022524

Suppliers and Packaging for NDA: 022524

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZUPLENZ
ondansetron
FILM;ORAL 022524 NDA Galena Biopharma, Inc. 57881-444 57881-444-01 1 POUCH in 1 BOX (57881-444-01) > 1 FILM, SOLUBLE in 1 POUCH
ZUPLENZ
ondansetron
FILM;ORAL 022524 NDA Galena Biopharma, Inc. 57881-444 57881-444-10 10 POUCH in 1 BOX (57881-444-10) > 1 FILM, SOLUBLE in 1 POUCH

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM;ORALStrength4MG
Approval Date:Jul 2, 2010TE:RLD:Yes
Patent:► SubscribePatent Expiration:Nov 23, 2029Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Jul 13, 2030Product Flag?YSubstance Flag?Delist Request?

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:FILM;ORALStrength8MG
Approval Date:Jul 2, 2010TE:RLD:Yes
Patent:► SubscribePatent Expiration:Nov 23, 2029Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Cerilliant
Fuji
Medtronic
Daiichi Sankyo
Express Scripts
US Department of Justice
Dow
Fish and Richardson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot